Literature DB >> 20882053

Readministration of helper-dependent adenoviral vectors to mouse airway mediated via transient immunosuppression.

H Cao1, T Yang, X-F Li, J Wu, C Duan, A L Coates, J Hu.   

Abstract

The efficacy of adenovirus-mediated gene therapy is attenuated by the host immune responses to both vector and transgene products. Even for helper-dependent adenoviral (HD-Ad) vectors, which have all viral-coding sequences deleted, the viral capsid proteins still cause immune reactions. In order to improve the efficiency in transgene expression during HD-Ad vector readministration, we administered cyclophosphamide to transiently modulate the mouse immune system. We delivered a high dose (5 × 10(10) vector particles (vp) per mouse) of empty HD-Ad to the mouse airway to induce an initial immune response. After 4 weeks, the mice were readministered with an HD-Ad vector containing either the reporter gene, LacZ, or the gene for the human cystic fibrosis transmembrane conductance regulator (CFTR) (1.5 × 10(10) vp per mouse). We found that the expression of both transgenes was greatly improved by the administration of cyclophosphamide when compared with the expression in mice without the immunosuppressing drug. We also found that the high dose of the empty HD-Ad vector administered intranasally does not induce an acute systemic immune response, but it does elicit an acute local response of proinflammatory cytokine production. Antibodies against Ad vector, including the neutralizing antibodies, were greatly reduced by the presence of cyclophosphamide in vector readministratiton. Moreover, cyclophosphamide reduced the infiltration of inflammatory cells, including total leukocytes, lymphocytes, CD4+ and CD8+T cells. These results indicate that transient administration of immunosuppressive agent can be used to extend transgene expression as well as attenuating immunogenicity to HD-Ad vectors in airway readministration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20882053     DOI: 10.1038/gt.2010.125

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  19 in total

Review 1.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

Review 2.  Genetic therapies for cystic fibrosis lung disease.

Authors:  Patrick L Sinn; Reshma M Anthony; Paul B McCray
Journal:  Hum Mol Genet       Date:  2011-03-21       Impact factor: 6.150

Review 3.  Advances in cell and gene-based therapies for cystic fibrosis lung disease.

Authors:  Mayumi Oakland; Patrick L Sinn; Paul B McCray
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

4.  Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression.

Authors:  C Unzu; I Melero; S Hervás-Stubbs; A Sampedro; U Mancheño; A Morales-Kastresana; I Serrano-Mendioroz; R E de Salamanca; A Benito; A Fontanellas
Journal:  Gene Ther       Date:  2015-07-23       Impact factor: 5.250

5.  Hybrid nonviral/viral vector systems for improved piggyBac DNA transposon in vivo delivery.

Authors:  Ashley L Cooney; Brajesh K Singh; Patrick L Sinn
Journal:  Mol Ther       Date:  2015-01-05       Impact factor: 11.454

Review 6.  Ferret and pig models of cystic fibrosis: prospects and promise for gene therapy.

Authors:  Ziying Yan; Zoe A Stewart; Patrick L Sinn; John C Olsen; Jim Hu; Paul B McCray; John F Engelhardt
Journal:  Hum Gene Ther Clin Dev       Date:  2015-02-12       Impact factor: 5.032

7.  Central nervous system delivery of helper-dependent canine adenovirus corrects neuropathology and behavior in mucopolysaccharidosis type VII mice.

Authors:  Lorena Ariza; Lydia Giménez-Llort; Aurélie Cubizolle; Gemma Pagès; Belén García-Lareu; Nicolas Serratrice; Dan Cots; Rosemary Thwaite; Miguel Chillón; Eric J Kremer; Assumpció Bosch
Journal:  Hum Gene Ther       Date:  2014-01-23       Impact factor: 5.695

8.  Adenovirus Biodistribution is Modified in Sensitive Animals Compared to Naïve Animals.

Authors:  Ana Sandoval-Rodríguez; Mayra Mena-Enriquez; Jesús García-Bañuelos; Adriana Salazar-Montes; Mary Fafutis-Morris; Monica Vázquez-Del Mercado; Arturo Santos-García; Juan Armendariz-Borunda
Journal:  Mol Biotechnol       Date:  2020-04       Impact factor: 2.695

9.  Functional Rescue of F508del-CFTR Using Small Molecule Correctors.

Authors:  Steven Molinski; Paul D W Eckford; Stan Pasyk; Saumel Ahmadi; Stephanie Chin; Christine E Bear
Journal:  Front Pharmacol       Date:  2012-09-26       Impact factor: 5.810

Review 10.  Potential of helper-dependent Adenoviral vectors in CRISPR-cas9-mediated lung gene therapy.

Authors:  Ranmal Avinash Bandara; Ziyan Rachel Chen; Jim Hu
Journal:  Cell Biosci       Date:  2021-07-23       Impact factor: 7.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.